Spinal Muscular Atrophy in Iceland has a high incidence rate of 13.9 per 100,000 live births and a point prevalence of 5.9 per 100,000 residents.
The incidence and point prevalence of SMA in Iceland are high compared to those reported in other countries.
Absolute Event Rate: 0% vs 0%
Introduction Spinal Muscular Atrophy (SMA) is a hereditary neuromuscular disorder characterized by the progressive degeneration of motor neurons and the subsequent loss of muscle function. With new therapeutic options for SMA, it is important to understand the epidemiology of the disease. As of January 2024, SMA has been included in newborn screening in Iceland. Objective To estimate the point prevalence and incidence rate of SMA in Iceland. Methods This retrospective, population-based study collected data from the institutional records of the University Hospital of Iceland, paediatricians and privately practising neurologists. The incidence period was from 1997 to 2024, and the point-prevalence day was January 1st 2025. The incidence was calculated per 100,000 live births and the point prevalence per 100,000 residents. Results On the prevalence day, 23 individuals had SMA in Iceland, resulting in a point prevalence of 5.9/100,000. The prevalence of SMA in children under 18 years was 10.6/100,000. During the incidence period, 17 cases of SMA were born, yielding an incidence rate of 13.9/100,000 live births. Of those born during the incidence period, twelve were alive on the prevalence day, resulting in a fatality rate of 29.4%. Two cases of SMA have been diagnosed through newborn screening since it began. Discussion The incidence and point prevalence of SMA in Iceland are high compared to those reported in other countries.
Sveindóttir et al. (Thu,) reported a other. Spinal Muscular Atrophy in Iceland has a high incidence rate of 13.9 per 100,000 live births and a point prevalence of 5.9 per 100,000 residents.